Talk:Mikael Dolsten

Update Job title

 * His job title should be updated to the Chief Scientific Officer and the President of Pfizer Research and Development to reflect the recent update in organizational structure. ' :

SarahB53 (talk) 15:06, 29 August 2023 (UTC)

✅ Spintendo  01:22, 30 August 2023 (UTC)


 * Hi Spintendo,
 * Thank you for the review. However, I'd like to point out that Mikael Dolsten's new role is "Chief Scientific Officer, President, Pfizer Research & Development" (copied from MM+M - Medical Marketing and Media article). "Chief Oncology Research and Development Officer and EVP" is Chris Boshoff's new title, not Mikael's.
 * Could you please update it? Thank you.
 * Best,
 * SarahB53 (talk) 19:17, 30 August 2023 (UTC)
 * I've reverted the changes I made. To make a new request, please submit it below. Please note that a verbatim description of the text to be added must be included with the request. Your text, which states " I'd like to point out that Mikael Dolsten's new role is "Chief Scientific Officer, President, Pfizer Research & Development" (copied from MM+M - Medical Marketing and Media). "Chief Oncology Research and Development Officer and EVP" is Chris Boshoff's new title, not Mikael's." is not encyclopedic, and cannot be added in that manner.


 * To expedite your request, it would help if you could provide the following information:
 * 1) Please state each specific desired change and accompanying reference in the form of verbatim statements which can then be added to the article (if approved) by the reviewer.
 * 2) The exact location where the desired claims are to be placed should be given.
 * 3) Exact, verbatim descriptions of any text and/or references to be removed should also be given.
 * 4) Reasons should be provided for each change.
 * In the section of text below titled Sample edit request, the four required items are shown as an example:

 1. Please remove the third sentence from the second paragraph of the Sun section:
 * "The Sun's diameter is estimated to be approximately 25 miles in length."

2. Please add the following claim as the third sentence of the second paragraph of the Sun section:
 * "The Sun's diameter is estimated to be approximately 864,337 miles in length."

3. Using as the reference:

4. Reason for change being made:
 * "The previously given diameter was incorrect."

Regards, Spintendo  23:13, 7 September 2023 (UTC)
 * Kindly open a new edit request at your earliest convenience when ready to proceed with all four items from your request. Thank you!

Request edit: Early Life

 * Can you please update the last sentence of “Early life” section in the article with accurate information?: “He pursued scientific studies in immunology and virology at the Weizmann Institute of Science in the 1980s." :

SarahB53 (talk) 19:04, 6 September 2023 (UTC)


 * Please provide secondary sources for this information. Spintendo  23:13, 7 September 2023 (UTC)

Edit Request - Job Title Update
“Mikael Dolsten (born c. 1958) is a Swedish-American physician scientist, and the President of research & development-Medical (chief scientific officer) of the American Pharmaceutical company Pfizer. ”
 * '''Please remove the first sentence from the main section:

“Mikael Dolsten (born c. 1958) is a Swedish-American physician scientist, and the Chief Scientific Officer and the President of Pfizer Research & Development of the American Pharmaceutical company Pfizer. ” ''' Masson, G. (2023, July 28). Chutes & Ladders-Pfizer exec out the door in R&D shake-up. Fierce Biotech. https://www.fiercebiotech.com/biotech/chutes-ladders-pfizer-exec-out-door-rd-shake : “To reflect his current position and title.”
 * '''Please add the following to the main section:
 * '''Using as the reference:
 * '''Reason for change being made:

SarahB53 (talk) 21:16, 8 September 2023 (UTC)

✔️ This title is already reflected in the lead. Changing the word sequence preference is merely window dressing. Regards, Spintendo  22:22, 10 September 2023 (UTC)

Pfizer’s Acquisition of Pharmacia
“This company would be bought by Pfizer in 1997.” ''': “Pfizer agreed to acquire Pharmacia in 2002 and the merger closed in 2003.” ''':
 * '''Please remove the last sentence from the Pharmacia section of Career section:
 * '''Please add the following to the Pharmacia section of Career section:
 * '''Using as the reference:

Politico. (2002, July 24). PHARMACEUTICAL – Pfizer buys Pharmacia. Politico. https://www.politico.eu/article/pharmaceutical-pfizer-buys-pharmacia/

CNN Money. (2003, April 16). It’s official: Pfizer buys Pharmacia. CNN Money. https://money.cnn.com/2003/04/16/news/companies/pfizer_pharma/: ''': To reflect the accurate information. ''':
 * '''Reason for change being made:

SarahB53 (talk) 21:57, 25 September 2023 (UTC)

✅ IMHO the COI editor should focus on adding more substantial secondary-source references to the article, rather than window-dressing type changes. Those types of improved references (including adding references to substantial information which is unreferenced) would benefit the article greatly. Spintendo 20:23, 26 September 2023 (UTC)

Update Source Request – Early Life and Career: Pharmacia sections

 * Please add the following reference to the below sentences:

Early Life section

“He is Jewish.”

“He pursued scientific studies in immunology and virology 1981 at the Weizmann Institute of Science in Rehovot Israel.”

Career: Pharmacia section

“Dolsten worked from 1988 to 1997 for the Swedish company Pharmacia in Lund. The last few years in this period he served as head of research for the Lund research center working in immune and cancer therapeutics.”


 * Friedman, G. (2020, November 16). Mikael Dolsten, the Jewish immigrant leading Pfizer’s vaccine charge, hopes the US stays a melting pot. Jewish Telegraphic Agency. https://www.jta.org/2020/11/16/health/mikael-dolsten-the-jewish-immigrant-leading-pfizers-vaccine-charge-hopes-the-us-stays-a-melting-pot '''


 * Jewish Telegraphic Agency has 456,012 Unique Monthly Visitors (data obtained via Similarweb) and is a noteworthy secondary source.

SarahB53 (talk) 19:31, 1 November 2023 (UTC)

Reply 1-NOV-2023
Regards, Spintendo  00:34, 2 November 2023 (UTC)
 * 1) The simple phrase He is Jewish appears, on its own, not to be very encyclopedic in its prosaic appearance, no matter how genuine and accurate the statement appears to be. I would suggest placing the phrase within another sentence — either newly proposed or perhaps an existing one already in the article — so that its appearance in the text to the reader as only 3 words is not so abrupt.
 * 2) He pursued scientific studies in immunology and virology 1981 at the Weizmann Institute of Science in Rehovot Israel it is not clear what is meant by the phrase "he pursued". Needless to say, the pursuit of studies in most countries entails pursuit of a degree of some sort. This sentence would benefit from an elaboration of that kind. Please advise.
 * 3) The information concerning the subject's position as "head of research" did not include a Wikilink for the company at which the subject worked. The COI editor is kindly urged to include this information in future requests.

Update Request – Early Life and Career: Pharmacia sections
'''Early Life Section
 * In the first paragraph of the Early Life section, can you remove “He was born Mikael Dolsten. He is Jewish”? In the second paragraph, can you remove “He grew up in Halmstad Municipality in the south-west of Sweden”?
 * And replace with “He was born in 1958 as Mikael Dohlsten to Jewish parents in the Halmstad Municipality on the Swedish west coast. ”

+++


 * In the third paragraph, can you remove “He studied medicine from January 1979 to 1985 at Lund University in Sweden and obtained a PhD in cancer immunology 1988 at Lund University. Dolsten was appointed associate professor 1990 and adjunct professor in immunology 1996” and “He pursued scientific studies in immunology and virology 1981 at the Weizman Institute of Science in Rehovot Israel”?
 * And replace with “He studied medicine at Lund University where he trained as a physician and later earned a PhD in tumor immunology from 1979 to 1988. Dolsten also spent nearly a year of his doctorate studies at the Weizmann Institute of Science in Rehovot, Israel. Dolsten was appointed associate professor and adjunct professor of immunology at Lund University upon completion of his doctorate. ”

+++

'''Career Section - Pharmacia


 * In the Pharmacia section, can you remove “Dolsten worked from 1988 to 1997 for the Swedish company Pharmacia in Lund. The last few years in this period he served as head of research for the Lund research center working into immune and cancer therapeutics”?
 * And replace with “From 1988 to 1997, Dolsten was involved in building up operations for the Swedish company Pharmacia in Lund, where he later served as research manager. ”

SarahB53 (talk) 18:55, 16 November 2023 (UTC)

✅ Spintendo  01:16, 17 November 2023 (UTC)

Update Source Request – Career: AstraZeneca and Pfizer sections
Can you update the AstraZeneca section into two sections (AstraZeneca and Boehringer Ingleheim) as below?

AstraZeneca

From 1997 to 2003, he worked for the Swedish pharmaceutical company Astra AB, which later merged with the British company Zeneca and became AstraZeneca, as head of research.

Boehringer Ingelheim 

Dolsten served as Executive Vice President, Pharma Research for Boehringer Ingelheim and then relocated to their U.S. office.

+++

Can you update the first paragraph of the Pfizer section as below?

Pfizer

Dolsten led Wyeth’s Research and Development and after the close of the Wyeth acquisition in 2009, he was named President of Pfizer’s BioTherapeutics Research & Development. He became the global chief of Pfizer research and development in May 2010, replacing Martin Mackay. In July 2023, his role expanded to Chief Scientific Officer, President, Pfizer Research & Development to lead all discovery, early- and late-stage clinical development, for all non-oncology therapeutic areas.

+++

References

1. DePalma, A. (1998, December 9). “Astra, Zeneca to Merge”. Pharmaceutical Online. Retrieved 15 December 2023. Pharmaceutical Online has 32,957 Unique Monthly Visitors (data obtained via Similarweb) and is a noteworthy secondary source.

2. “IVAs Guldmedalj 2021: Mikael Dolsten”. IVA. 20 March 2023. Retrieved 15 December 2023. The Royal Swedish Academy of Engineering Sciences (IVA) has 7,498 Unique Monthly Visitors (data obtained via Similarweb) and is a noteworthy secondary source.

3. “Boehringer and Yale Combine Strengths in New Research Alliance”. Yale Medicine. March-April 2006. Retrieved 15 December 2023. Yale Medicine has 1,505,273 Unique Monthly Visitors (data obtained via Similarweb) and is a noteworthy secondary source.

4. Friedman, G. (17 November 2020). “Mikael Dolsten, Jewish Immigrant and Top Pfizer Scientist, Hails US Melting Pot”. The Times of Israel. Retrieved 15 December 2023. The Times of Israel has 24,028,472 Unique Monthly Visitors (data obtained via Similarweb) and is a noteworthy secondary source.

5. Friedman, G. (16 November 2020). “Mikael Dolsten, the Jewish Immigrant Leading Pfizer’s Vaccine Charge, Hopes the US Stays a Melting Pot”. Jewish Telegraphic Agency. Retrieved 15 December 2023. The Times of Israel has 771,950 Unique Monthly Visitors (data obtained via Similarweb) and is a noteworthy secondary source.

6. “Pfizer Completes $67 Billion Deal for Rival Wyeth”. Reuters. 15 October 2009. Retrieved 13 December 2023. Reuters has 54,756,032 Unique Monthly Visitors (data obtained via Similarweb) and is a noteworthy secondary source.

7. Taylor, N. (1 June 2010). “Pfizer and AstraZeneca naming R&D Leaders and Appointments at APV and Lonza – People on the Move”. Outsourcing Pharma. Retrieved 15 December 2023. Outsourcing Pharma has 31,781 Unique Monthly Visitors (data obtained via Similarweb) and is a noteworthy secondary source.

8. Carroll, J. (26 May 2010). “Mackay Moves to AZ as Dolsten Takes Pfizer’s R&D Crown”. Fierce Biotech. Retrieved 15 December 2023. Fierece Biotech has 506,921 Unique Monthly Visitors (data obtained via Similarweb) and is a noteworthy secondary source.

9. O’Brien, J. (27 July 2023). “Pfizer Elevates Chris Boshoff to Head R&D in Organizational Shakeup”. MM+M. Retrieved 13 December 2023. MM+M has 48,064 Unique Monthly Visitors (data obtained via Similarweb) and is a noteworthy secondary source.

+++

SarahB53 (talk) 21:38, 15 December 2023 (UTC)

I've omitted the different headings of the pharm companies because the information within them was of a size that is too small to justify having separate headings. The information on the subject's varying activities at Pfizer were not added, suffice it to say, that the subject worked at Pfizer is enough to state. The different activities they performed are not germane to the whole of the article, as this is WP:NOTRESUME. Regards, Spintendo  00:25, 19 December 2023 (UTC)